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Abstract The aim of this study was to provide a single site
resource for investigators, clinicians, and others seeking
preclinical, animal, and human investigational studies
concerning the postsurgical, anti-adhesion barrier Sepra-
film™ (Genzyme Corporation, Cambridge, MA). All pub-
lished preclinical, animal, human extra-abdominal research
as of July 2011 have been summarized and included in this
document. Searches of Medline and EMBASE Drugs and
Pharmaceuticals databases were conducted for original pre-
clinical, animal, and human extra-abdominal studies involv-
ing Seprafilm. Preclinical, animal, and extra-abdominal
human investigational studies are the study selection for this
manuscript. Intraabdominal use is discussed in the accom-
panying manuscript. Data extraction includes systematic
manuscript review. Summary of preclinical, animal, and
extra-abdominal human investigational use of Seprafilm by
surgical discipline were gathered for data synthesis. The
clinical use of Seprafilm, which was approved by the FDA
for intra-abdominal procedures, is supported by preclinical
and animal studies relating to general surgical and obstetri-
cal/gynecological applications. Findings from preclinical,
animal, and human investigational studies at other sites
throughout the body raises the potential for additional hu-
man clinical trials to assess efficacy and safety following
surgical procedures at non-abdominal locations.
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Introduction
Postoperative adhesions lead to significant patient morbidity
such as small bowel obstruction, infertility, chronic pain, and
difficult, complicated subsequent surgeries. Various strategies
have been put forth to prevent adhesion development includ-
ing meticulous surgical techniques, pharmacological agents,
and new equipment and instrumentation. Yet, despite these
interventions, the overwhelming majority of patients continue
to develop adhesions after surgical procedures.
Pathogenesis of adhesions
Considerations for adhesion prevention should be based
upon an understanding of peritoneal repair, and what goes
awry when adhesions develop, as briefly summarized below
[1–3]. Postoperative adhesion development is teleologically
considered to be an effort by the body to restore the supply
of oxygen and nutrients to tissue which has been injured
during the surgical procedure. As a sequelae to tissue injury,
an inflammatory-like response occurs in response to
surgery-induced tissue hypoxia, with resultant generation
of reactive oxygen and reactive nitrogen species. This
inflammatory response invokes release of histamine,
cytokines, and growth factors; infiltration of polymorpho-
nuclear leukocytes; and the migration of fibroblasts from
underlying tissues. Collections of blood and serosangui-
nous tissue exudates occur on the surface of injured
tissue forming a fibrinous mass. In the presence of di-
minished or absent tissue plasminogen activator activity,
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the fibrinous mass persists long enough for infiltration by
the migrating fibroblasts from the underlying tissues,
with subsequent deposition of extracellular matrix includ-
ing collagen and fibronectin. Persistence of relative hypox-
ia induces vascular endothelial growth production with
subsequent angiogenesis. This process persists during and
beyond the 3 to 5 days required for remesotheliazation of
injured tissue surfaces.
If this concept of adhesion development is correct, then
the critical time to prevent or diminish adhesion development
is in the initial 3 to 5 days after the surgical procedure, prior to
completion of remesotheliazation. Additionally, adjuvants
and approaches to reduce adhesions would either interrupt
the molecular biologic process leading to adhesion develop-
ment and/or physically separate opposing tissue surfaces
at risk for adhesion development until after remesothe-
liazation is complete. It is this latter approach which
has been utilized by all of the FDA-approved devices
for the reduction of postoperative intra-abdominal and
pelvic adhesions, including Seprafilm. This manuscript
summarizes the preclinical, animal, and human investi-
gational studies involving Seprafilm. A companion
manuscript summarizes reports of intra-abdominal use
of Seprafilm for general surgical and gynecological
operative procedures.
Seprafilm adhesion barrier
Physical properties and clearance
Seprafilm is a bioresorbable membrane composed of
sodium hyaluronate (HA) and carboxymethylcellulose
(CMC) which have been chemically modified to delay
the rate of degradation and clearance after placement in
the body. Seprafilm is applied to the surface of tissues to
be protected and hydrates to form a lubricious gel coat-
ing within 24 to 48 h of placement. The hydrophilic
protective gel acts as physical barrier to separate adjacent
serosal tissues during the critical stages of wound repair
and has no pharmacological effect. During the transition
from a solid to gel, the volume of the barrier increases,
but its swelling pressure decreases from 6.4 atm to 0. In
addition, Seprafilm’s tensile strength decreases by 90 %
within 30 min. The membrane’s swelling does not affect
peritoneal tissue or organ function. The barrier is
resorbed from the site of application within 7 days and
therefore does not require a second operation for remov-
al. Radiolabeled studies of Seprafilm showed that it is
totally cleared from the body within 28 days following
implantation. Seprafilm is excreted primarily through the
kidneys. Seprafilm’s rapid degradation reduces the risk of
a foreign body tissue response [4].
Preclinical safety and efficacy studies
The safe and effective use of Seprafilm in the abdominal
cavity of animals has been reported in a number of publica-
tions using multiple species and models of abdominal sur-
gery [4–34]. In these models, the use of Seprafilm was
reported to be efficacious in reducing adhesions, including
in the presence of blood and irrigation solution [4], in
combination with melatonin [33] and under ischemic con-
ditions [4]. When used in multiple layers [4], Seprafilm did
not adversely affect wound healing [4, 6, 8, 35], did not
affect anastomotic healing with [36] or without concomitant
ischemia [35, 37], and did not potentiate intra-abdominal
sepsis [11, 38]. In general, Seprafilm use has been reported
not to have adverse effects [5, 7, 9, 10, 12, 13, 39–41].
Concomitant radiotherapy did not alter the efficacy [42];
however, the efficacy of Seprafilm was reduced in the
presence of peritonitis [43].
In addition, the use of Seprafilm in animal models has
been reported from a number of anatomical sites outside of
the abdominal cavity, including following nerve repair [44]
and cancer treatment [45–48]. In this series of articles, the
application of Seprafilm did not increase cancer cell growth,
wound site implantation, or distant metastasis and did not
decrease host survival. Additionally, Seprafilm has been
reported to be safe and beneficial when used in conjunction
with cardiac surgery [49–51], tendon surgery [52], joint
surgery [53], spinal surgery [54–56], strabismus surgery
[57], and tympanic membrane surgery [58].
Multiple preclinical safety studies in various animal
models have been conducted to assess the immunogenicity,
biocompatibility, and tissue response to Seprafilm [4].
Dermal and systemic immunogenicity (using sodium
hyaluronate–carboxymethylcellulose (HA-CMC) extracts)
were studied with two series of intradermal injections in
15 adult albino guinea pigs, and by six intraperitoneal
injections in ten adult guinea pigs over a period of
2 weeks followed by an intravenous challenge injection,
respectively [4]. Dermal injection sites were observed for
erythema and edema over a 96-h period; no indications
of dermal sensitization were observed. In addition, no
systemic response suggestive of antigenecity or anaphylaxis
was observed after multiple intraperitoneal injections
followed by an intravenous challenge injection.
Biocompatibility was assessed through studies of in
vitro hemolysis, in vitro complement activation, in vitro
cytotoxicity, and muscle implant tests [4]. In all cases,
Seprafilm did not elicit reactions suggestive of tissue
incompatibility. Tissue response to Seprafilm was examined
in a rat model by abrading the rat cecum, followed by either
the application of Seprafilm (treatment group) or no further
intervention (untreated group). Animals were observed for
28 days; inflammatory cells including macrophages were
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noted at day 2 in both groups. At day 4, a large number of
macrophages (no giant cells) were observed in the treat-
ment group suggestive of HA-CMC degradation, while
the untreated group displayed fewer macrophages and
occasional polymorphonuclear cells, suggestive of the
normal wound healing process. At day 28, the rat cecum
appeared to be healed in both groups, but the untreated
group had denser granulation tissue at the wound site.
Additionally, the Ames mutagenicity test, the rabbit pyrogen
test, the intracutaneous toxicity test, and the acute intraperito-
neal and systemic toxicity tests, respectively demonstrated
that Seprafilm is biocompatible, non-mutagenic, non-
pyrogenic, non-irritating, and nontoxic [4].
Preclinical evaluation of the efficacy of Seprafilm in a
rat cecal abrasion or side wall injury model demonstrated
that Seprafilm significantly reduced the incidence of cecal
adhesions (P<0.001) and the number of animals with severe
adhesions (P<0.001) when compared with non-treated
controls [4]. This efficacy was maintained in the presence of
blood, excess irrigation fluids, and layering of Seprafilm, as
well as under ischemic conditions. Subsequently, in cell
culture studies of human peritoneal and adhesion fibroblasts,
Seprafilm was not observed to alter expression of inflamma-
tory markers such as type I collagen and transforming growth
factor beta [59].
Efficacy of Seprafilm has also been demonstrated in an
adhesion reformation model [33]. In this study, adhesion
reformation was induced between the uterine horns by
creation of ten standardized lesions on the uterine horns
using bipolar electrocoagulation, with separation from
tissue lying above and below with Seprafilm. Adhesiolysis
was performed at the time of a second-look procedure with
randomization to one of four groups: control, Seprafilm alone,
melatonin (a free radical scavenger) alone (1 ml of a 2-mg/ml
solution), or a combination of Seprafilm plus melatonin. At
the time of a third-look procedure, adhesion reformation was
significantly reduced by either Seprafilm or melatonin alone
compared to control animals, with a further significantly
greater reduction in adhesion reformation achieved with the
combination of Seprafilm plus melatonin [33].
Use of Seprafilm with specific conditions
Infection
The effect of Seprafilm on abscess development was studied
in three independent animal studies in which Seprafilm was
placed in the presence of existing peritonitis. In two of those
studies, Seprafilm had no effect on abscess development
[60] while in a third study Seprafilm was associated with
increased abscess development when placed in the presence
of ongoing peritonitis [43]. Although these results are in-
consistent, the Seprafilm label directs users not to use the
product in the presence of frank infection. Additional work
in experimental models have shown that Seprafilm had no
effect on sepsis or abscess development when Seprafilm
placement was concomitant with bacterial contamination
[38] when placed in a surgical model of bowel injury
[11] and that it did not exaggerate intra-abdominal septic
conditions or induce a systematic inflammatory response
[61].
To further elucidate mechanistic aspects of the possible
impact of Seprafilm on infectious processes, Otake et al.
examined the effect of Seprafilm in polymorphonuclear
(PMN) obtained from 14 subjects [62]. Seprafilm was
evaluated in two forms, as a film and after it was well
dissolved and compared to corresponding controls.
Seprafilm, in either form, had no effect on the rate of
phagocytosis of Escherichia coli or Staphylococcus aureus,
the rate of PMN-induced apoptosis of E. coli and S. aureus,
and the effect of PMN-induced necrosis of E. coli and S.
aureus. Examining cytokine production when co-cultured
with E. coli or S. aureus, Seprafilm also had no effect on
production of the cytokines IL-1α, IL-6, or IL-8 or on the
production of IL-1 RA or PMN elastase. There was also no
effect on PMN cytokine production when stimulated with
TNF-α or LPS.
Malignancy
In vitro studies did not find any increase in the growth of
colon cancer cells when cultured in the presence of Sepra-
film [45]. Preclinical studies in mouse or hamster models
did not observe any increase in cancer cell growth, wound
site implantation, distant metastasis, or host survival with
the use of Seprafilm in the presence of cancer cells, when
compared with the control [46–48].
Animal investigational studies of use of Seprafilm
Cardiac surgery
Preclinical studies in dogs, pigs, sheep, and rabbits evaluating
the use of Seprafilm in cardiac surgery observed a significant
decrease in the severity of pericardial adhesions in most
[49–51, 63], but not all studies [64].
Thoracic surgery
A preclinical study in sheep was done to assess the effect
of Seprafilm on pleural adhesion formation after experi-
mental thoracotomy and parietal pleurectomy [65]. A
significant decrease in the incidence (P<0.001) and se-
verity (P<0.001) of the pleural adhesions was noted in
the Seprafilm group when compared with control. There
was no increase in inflammation in the areas of Seprafilm
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application. A preclinical study in rats was unable to identify a
benefit or detriment when the esophagus was wrapped with
Seprafilm or Interceed, as assessed by adhesion score 3 weeks
later or by hyroxyproline levels [66].
Vascular surgery
To investigate whether external support would reduce
intimal hyperplasia at the site of venous graft anastamosis,
rabbits undergoing bypass grafting of the right jugular
vein to the right common carotid artery was performed in
the presence or absence of wrapping the anastamosis
with Seprafilm [67]. Evaluation at 1 month demonstrated
that use of Seprafilm reduced both neointimal and medial
thickening.
Orthopedic surgery
In a preclinical study, Seprafilm was used to prevent
adhesions after tenolysis at the flexor digitorum tendon
in chickens [52]. Six weeks after the application of
Seprafilm, tendons that received Seprafilm were seen
to have a significantly improved gliding excursion pro-
file (P<0.05) and decreased incidence of adhesions
(P<0.05), when compared with controls. Consistent
results were observed in a chicken gastrocnemius tendon
model, in which Seprafilm wrapping resulted in im-
proved tendon sheath complex sliding, less histological
evidence of tissue inflammation, and greater tendon ten-
sile strength, as compared to untreated controls [68].
Similarly, in a rabbit partial-thickness flexor tendon inju-
ry–suture repair model, comparing Seprafilm and other HA-
based products versus controls, there was a reduction in
both the gross adhesion score and the histologic adhesion
score and an improvement in histologic assessment of tender
healing [69]. In a biomechanical test, the force required to
remove the tendon from its sheath was less for Seprafilm than
injured, untreated control animals.
The safety of Seprafilm use in femorotibial joints was
studied in adult female New Zealand White rabbits [53].
Intraarticular administration of Seprafilm in femorotibial
joints of rabbits was associated with transient uptake by
synovial phagocytes, but no local toxicity was apparent for
up to 6 months.
Three studies have evaluated Seprafilm after laminec-
tomy. The first preclinical study compared the effect of
Seprafilm and GORE-TEX membrane in preventing peri-
dural fibrosis after spinal surgeries in rats [55]. Seprafilm or
Gore-Tex was applied to a laminectomy defect overlying the
dura mater and evaluated 2 months later. Both membranes
facilitated access to the epidural space and provided a re-
duction in the amount of tissue adhering to the dura mater.
There was a statistically significant decrease in the peridural
adhesions with the use of Seprafilm when compared with
the Gore-Tex membrane. The second study evaluated rats
that underwent hemilaminectomy at L4 and L5 followed by
treatment with Seprafilm or Interceed [56]. Both agents
significantly reduced epidural fibrosis and dural adhesions
at 4 and 8 weeks evaluation. The third study compared
ADCON-L to Seprafilm in a rat laminectomy model. Both
products were found to be effective in reducing peridural
adhesions [54].
Seprafilm has also been evaluated to determine its effects
on peripheral nerves, in models, both with and without
nerve injury [70]. In the former, Seprafilm was placed either
superficially to the nerve or wrapped circumferentially
around the nerve. In both cases, Seprafilm had no effect
on the nerve at evaluation times up to 6 weeks, as assessed
by nerve compression, nerve fibrosis or inflammation, foreign
body reaction, or nerve ultrastructure, vascularity, and
histomorphology. It was also noted that there were qualita-
tively fewer adhesions at the operative site, with preservation
of the surgical plane medial to the gluteal muscle. In the nerve
injury model in which the sciatic nerve was severed and then
repaired, Seprafilm treatment was associated with less
perinural adhesions. The histomorphological findings favored
Seprafilm at the initial evaluation period (18 days) and control
at the final evaluation period (42 days), although no functional
outcome differences were identified [70].
Opthalmic surgery
In a preclinical study, Seprafilm has been used to prevent
conjunctival adhesions after strabismus surgery [57]. Sepra-
film was applied to the eyes of New Zealand rabbits after
dissection in the area of the superior fornix and inferior
conjunctival limbus. Six weeks after the initial procedure,
eyes in which Seprafilm was applied showed significantly
less fibrosis, both at the area of superior rectus resection
(P<0.046) and the area of conjunctival dissection (P<0.015)
as compared to the control areas. No increase in inflammation
was observed at the areas of application of Seprafilm. In other
ophthalmic studies, adhesion development in rabbits was
reduced by Seprafilm after creation of either conjunctival
flaps or when applied above and below scleral flaps [71].
Additionally, Seprafilm application in subconjuctival pockets
was associated with a reduction in the mean adhesive force
between the sclera and conjunctiva, while placement of
Seprafilm on the scleral flap after trabeculectomy
resulted in a larger subconjuctival space and reduced
intraocular pressure as compared to control rabbits [72].
Seprafilm was subsequently used experimentally for
patching of small retinal breaks in a rabbit model of
rhegmatogenous retinal detachment [73]. In treated animals,
retinal reattachments were identified, as contrasted to
proliferative vitreoretinopathy in the control group.
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Otologic surgery
Adhesions in the middle ear can contribute to conductive
hearing loss, as well as tympanic membrane retraction. In a
study of guinea pigs, abrasion of the middle ear mucosa
through a myringotomy incision was used to create adhe-
sions and evaluate their reduction by Seprafilm [74]. In
contrast to control animals, those that had received Sepra-
film packing at the conclusion of the surgical procedure had
no middle ear cleft adhesions and no differences in auditory
brainstem responses at 3 or 6 weeks after surgery [74].
Human investigational uses of Seprafilm
Intrauterine
In a prospective, blinded, randomized, controlled study,
Seprafilm was studied for adhesion prevention after the
suction and/or curettage evacuation of the uterus in 150
women (Table 1) [75]. Seprafilm was applied following
the procedure. One Seprafilm membrane was cut into two
equal pieces, then rolled and inserted through the end cer-
vical canal into the endometrial cavity. The end point of the
study was pregnancy or demonstration of adhesions on
hysterosalpingography. Among the women with no prior
history of dilatation and curettage (D&C), 100 % of
Seprafilm-treated women achieved pregnancy within
8 months of the procedure, compared with 54 % of the
control women who became pregnant during the same in-
terval of time. Of the women with prior history of D&C,
33 % of the Seprafilm-treated women and 22.7 % of the
control women became pregnant. Hysterosalpingography in
women, who had not become pregnant, revealed adhesions
in 10 % of the Seprafilm-treated women and 50 % of the
control group of women.
Cardiac surgery
In a prospective clinical study in patients undergoing coro-
nary artery bypass graft surgery, the median percentage of
retrosternal adhesions in the group that received Seprafilm
was 53 % (range 27–88 %) versus 71 % (range 18–90 %) in
patients who did not receive Seprafilm. This difference was
not statistically significant [76].
Thoracic surgery
Seprafilm was utilized in 249 subjects with neurogenic
thoracic outlet syndrome [77]. The barrier was placed over
the fine nerve roots of the bronchial plexus at the conclusion
of the supraclavicular thoracic outlet decompression proce-
dure, in an attempt to reduce postoperative scarring. Success
rates for primary operations for scalenectomy with or without
Table 1 Investigational clinical publications and calculated effect size
Reference N Therapeutic area Favorable Seprafilm outcome Effect sizea Reported p value
van der Linden. [76] 19 Cardiac Median retrosternal adhesions Cannot be calculated, only median
and range reported
NS
Koyuncu et al. [78] 23 Vascular Internal jugular vein function n/a NS




Sanders et al. [77] 249 Neurologic 15 year old historical control group








Icinose et al. [84] n/a Neurologic No control group or efficacy n/a n/a
Assaf et al. [80] 4 Opthalmic No control group or efficacy n/a n/a
Taban et al. [81] 4 Opthalmic No control group or efficacy n/a n/a
Shibata et al. [82] 1 Opthalmic No control group n/a n/a
Filler et al. [79] 239 Orthopedic No safety, efficacy or control n/a n/a
Caylan et al. [83] 21 Otologic No control group n/a n/a
a For continuous outcomes, effect size is the (control group mean–the Seprafilm mean) divided by the pooled standard deviation for the two groups
[ES 0 (M1−M2)/pooled SD], and for binomial outcomes, effect size is the odds ratio or the ratio of the odds of a success for the Seprafilm group to
the odds of a success for the control group [ES 0 (ad)/(bc)]
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resection of the first rib was 70 and 74 %, respectively,
and 78 % for reoperative procedures. These results were
no different than historical controls, although reopera-
tions demonstrated a trend towards improvement in
symptoms. In ten patients who underwent reoperations,
it was thought there were reduced adhesions of the fat
pad to the nerve root, thereby facilitating identification of
the nerve roots.
Vascular surgery
In a small study of individuals undergoing functional
neck dissection, the impact of wrapping the jugular vein
with Seprafilm was evaluated [78]. Three months post-
operatively, Doppler ultrasound evaluation of internal
jugular vein function identified no differences in the
healing process.
Orthopedic surgery
Seprafilm was used as an adhesiolytic agent in patients who
underwent surgical treatment for release of sciatic nerve en-
trapment in the pelvis or at the level of the ischial tuberosity
[79]. No safety or efficacy assessments were made.
Opthalmic surgery
Seprafilm has been successfully used in four patients under-
going strabismus surgery. Seprafilm was inserted over the
muscle without complication. The authors reported the appli-
cation of Seprafilm to be safe in patients undergoing repeated
strabismus surgery [80]. In another report, Seprafilm was
applied in four subjects (six sites total) with orbital fractures
and entrapped orbital soft tissue [81]. Seprafilm was placed
over the fracture in these “trap doors”, with no subsequent
need for reoperation and with no complications. Lastly, Sepra-
film was used in one patient with neovascular glaucoma who
underwent bilateral trabeculectomy. The authors reported that
in this patient, trabeculotomy adjunct use of Seprafilm was
effective in controlling intraocular pressure, maintenance of
scleral flap, and prevention of adhesions between the scleral
flap and conjunctiva [82].
Otologic surgery
In a case series of 21 patients with middle ear and or mastoid
cholesteatoma, undergoing staged tympanoplasty with
mastoidectomy, Seprafilm was applied in the mastoid
cavity [83]. Seprafilm was reported to result in the preserva-
tion of the aeration of the mastoid cavity while preventing
retraction of postauricular skin. No adverse reactions were
reported.
Neurosurgery
Use of Seprafilm has been described in a series of 13
patients in whom the barrier was placed between the tem-
poral muscle and the dura at the time of cranioplasty for
external decompression for brain swelling [84]. Such use
was identified by the authors as facilitating subsequent
cranioplasties, by decreasing bleeding and operative time,
as well as injuries to the temporal muscle or dura.
Summary
Seprafilm has been extensively studied in intraperitoneal
clinical trials, demonstrating safety and efficacy in reducing
postoperative adhesion development after intra-abdominal
surgery. This report summarizes preclinical studies demon-
strating the time course and mechanism of Seprafilm degra-
dation. Additionally, key animal studies involving
procedures both intra-abdominally and elsewhere through-
out the body have been summarized, identifying efficacy
and safety at these diverse locations. Results of published
human investigational uses at non-abdominal locations
throughout the body have also been detailed. These findings
provide the opportunity for future randomized, controlled
clinical trials of Seprafilm outside the intra-abdominal cav-
ity, and also the foundation to further improve the efficacy
of anti-adhesion adjuvants, perhaps by using barriers (which
function separating traumatized surfaces during mesothelial
repair) to also serve as a device for local delivery of drugs
and/or biologics.
Conflict of interest Michael P. Diamond has acted as consultant to
the company. The authors alone are responsible for the content and
writing of the paper.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Ward BC, Panitch A (2009) Abdominal adhesions: current and
novel therapies. J Surg Res 165(1):91–111
2. Saed GM, Diamond MP (2004) Molecular characterization of
postoperative adhesions: the adhesion phenotype. J Am Assoc
Gynecol Laparosc 11(3):307–314
3. Imudia AN, Kumar S, Saed GM, Diamond MP (2008) Pathogen-
esis of intra-abdominal and pelvic adhesion development. Semin
Reprod Med 26(4):289–297
4. Burns JW, Colt MJ, Burgees LS, Skinner KC (1997) Preclinical
evaluation of Seprafilm bioresorbable membrane. Eur J Surg Suppl
577:40–48
242 Gynecol Surg (2012) 9:237–245
5. Greenawalt K, Masi L, Muir C, Burns J (1993) The physical
properties of a hyaluronic acid based bioresorbable membrane
for the prevention of post-surgical adhesions. Paper presented at
Mat Res Soc Symp Proc
6. Alponat A, Lakshminarasappa SR, Yavuz N, Goh PM (1997)
Prevention of adhesions by Seprafilm, an absorbable adhesion
barrier: an incisional hernia model in rats. Am Surg 63(9):818–819
7. Avsar AF, Avsar FM, Sahin M, Topaloglu S, Vatansev H, Belviranli
M (2003) Diphenhydramine and hyaluronic acid derivatives reduce
adnexal adhesions and prevent tubal obstructions in rats. Eur J Obstet
Gynecol Reprod Biol 106(1):50–54
8. Bulbuller N, Sapmaz E, Akpolat N, Ustundag B, Kirkil C (2003)
Effect of a bioresorbable membrane on postoperative adhesions
and wound healing. J Reprod Med 48(7):547–550
9. Saribeyoglu K, Pekmezci S, Ulualp K (2004) Seprafilm may ease
colostomy reversal. Arch Surg 139(12):1380–1382
10. Osada H, Minai M, Tsunoda I, Fujii TK, Tsubata K, Satoh K (1999)
The effect of hyaluronic acid–carboxymethylcellulose in reducing
adhesion reformation in rabbits. J Int Med Res 27(6):292–296
11. Moreira H Jr, Wexner SD, Yamaguchi T et al (2000) Use of
bioresorbable membrane (sodium hyaluronate + carboxymethyl-
cellulose) after controlled bowel injuries in a rabbit model. Dis
Colon Rectum 43(2):182–187
12. Hellebrekers BW, Trimbos-Kemper GC, van Blitterswijk CA,
Bakkum EA, Trimbos JB (2000) Effects of five different barrier
materials on postsurgical adhesion formation in the rat. Hum
Reprod 15(6):1358–1363
13. Buckenmaier CC 3rd, Pusateri AE, Harris RA, Hetz SP (1999)
Comparison of antiadhesive treatments using an objective rat mod-
el. Am Surg 65(3):274–282
14. Yamaner S, Kalayci M, Barbaros U, Balik E, Bulut T (2005) Does
hyaluronic acid–carboxymethylcellulose (HA-CMC) membrane
interfere with the healing of intestinal suture lines and abdominal
incisions? Surg Innov 12(1):37–41
15. Sahin M, Cakir M, Avsar FM, Tekin A, Kucukkartallar T, Akoz M
(2007) The effects of anti-adhesion materials in preventing
postoperative adhesion in abdominal cavity (anti-adhesion
materials for postoperative adhesions). Inflammation 30
(6):244–249
16. Numanoglu V, Cihan A, Salman B et al (2007) Comparison be-
tween powdered gloves, powder-free gloves and hyaluronate/car-
boxymethylcellulose membrane on adhesion formation in a rat
caecal serosal abrasion model. Asian J Surg 30(2):96–101
17. Kelekci S, Uygur D, Yilmaz B, Sut N, Yesildaglar N (2007)
Comparison of human amniotic membrane and hyaluronate/car-
boxymethylcellulose membrane for prevention of adhesion forma-
tion in rats. Arch Gynecol Obstet 276(4):355–359
18. Baca B, Boler DE, Onur E et al (2007) Icodextrin and Seprafilm do
not interfere with colonic anastomosis in rats. Eur Surg Res 39
(5):318–323
19. Bahadir I, Oncel M, Kement M, Sahip Y (2007) Intra-abdominal
use of taurolidine or heparin as alternative products to an antiad-
hesive barrier (Seprafilm) in adhesion prevention: an experimental
study on mice. Dis Colon Rectum 50(12):2209–2214
20. Kaptanoglu L, Kucuk HF, Yegenoglu A et al (2008) Effects of
Seprafilm and heparin in combination on intra-abdominal
adhesions. Eur Surg Res 41(2):203–207
21. Altuntas YE, Kement M, Oncel M, Sahip Y, Kaptanoglu L (2008) The
effectiveness of hyaluronan-carboxymethylcellulose membrane
in different severity of adhesions observed at the time of
relaparotomies: an experimental study on mice. Dis Colon
Rectum 51(10):1562–1565
22. Emre A, Akin M, Isikgonul I, Yuksel O, Anadol AZ, Cifter C (2009)
Comparison of intraperitoneal honey and sodium hyaluronate-
carboxymethylcellulose (Seprafilm) for the prevention of postopera-
tive intra-abdominal adhesions. Clin (Sao Paulo) 64(4):363–368
23. Ersoy E, Ozturk V, Yazgan A, Ozdogan M, Gundogdu H (2009)
Comparison of the two types of bioresorbable barriers to
prevent intra-abdominal adhesions in rats. J Gastrointest Surg
13(2):282–286
24. Irkorucu O, Ferahkose Z, Memis L, Ekinci O, Akin M (2009)
Reduction of postsurgical adhesions in a rat model: a comparative
study. Clin (Sao Paulo) 64(2):143–148
25. Lim R, Morrill J, Lynch R et al (2009) Practical limitations
of bioresorbable membranes in the prevention of intra-
abdominal adhesions. J Gastrointest Surg 13(1):35–41, discussion
41-32
26. Rajab TK, Wallwiener M, Planck C, Brochhausen C, Kraemer B,
Wallwiener CW (2010) A direct comparison of Seprafilm, adept,
intercoat, and spraygel for adhesion prophylaxis. J Surg Res 161
(2):246–249
27. Falabella CA, Melendez MM, Weng L, Chen W (2010) Novel
macromolecular crosslinking hydrogel to reduce intra-abdominal
adhesions. J Surg Res 159(2):772–778
28. Wiseman DM, Meidler R, Lyahovetsky Y, Kurman E, Horn S, Nur
I (2010) Evaluation of a fibrin preparation containing tranexamic
acid (Adhexil) in a rabbit uterine horn model of adhesions with and
without bleeding and in a model with two surgical loci. Fertil Steril
93(4):1045–1051
29. Lalountas MA, Ballas KD, Skouras C et al (2010) Preventing
intraperitoneal adhesions with atorvastatin and sodium hyaluro-
nate/carboxymethylcellulose: a comparative study in rats. Am J
Surg 200(1):118–123
30. Lo HY, Kuo HT, Huang YY (2010) Application of polycaprolac-
tone as an anti-adhesion biomaterial film. Artif Organs 34(8):648–
653
31. Kement M, Censur Z, Oncel M, Buyukokuroglu ME, Gezen FC
(2010) Heparin for adhesion prevention: comparison of three dif-
ferent dosages with Seprafilm in a murine model. Int J Surg 9:225–
228
32. Durmus AS (2010) Effect of Seprafilm on prevention of intra-
abdominal adhesions in rats. Indian Vet J 87:816–817
33. Attar R, Yildirim G, Kumbak B, Ficicioglu C, Demirbag S,
Yesildaglar N (2011) Efficacy of melatonin and hyaluronate/
carboxymethylcellulose membrane in preventing adhesion reforma-
tion following adhesiolysis in a rat uterine model. J Obstet
Gynaecol Res 37(2):125–131
34. Baptista ML, Bonsack ME, Delaney JP (2000) Seprafilm reduces
adhesions to polypropylene mesh. Surgery 128(1):86–92
35. van Oosterom F, van Lanschot J, Oosting J, Obertop H (2000)
Hyaluronic acid/carboxymethylcellulose membrane surrounding
an intraperitoneal or subcutaneous jejunojejunostomy in rats. Eur
J Surg 166(8):654–658
36. Erturk S, Yuceyar S, Temiz M et al (2003) Effects of hyaluronic
acid–carboxymethylcellulose antiadhesion barrier on ischemic
colonic anastomosis: an experimental study. Dis Colon Rectum
46(4):529–534
37. Medina M, Paddock HN, Connolly RJ, Schwaitzberg SD (1995)
Novel antiadhesion barrier does not prevent anastomotic healing in
a rabbit model. J Investig Surg 8(3):179–186
38. Tzianabos AO, Cisneros RL, Gershkovich J et al (1999) Effect
of surgical adhesion reduction devices on the propagation of
experimental intra-abdominal infection. Arch Surg 134
(11):1254–1259
39. Oncel M, Remzi FH, Senagore AJ, Connor JT, Fazio VW (2003)
Comparison of a novel liquid (Adcon-P) and a sodium hyaluronate
and carboxymethylcellulose membrane (Seprafilm) in postsurgical
adhesion formation in a murine model. Dis Colon Rectum 46
(2):187–191
40. Oncel M, Remzi FH, Senagore AJ, Connor JT, Fazio VW (2004)
Application of Adcon-P or Seprafilm in consecutive laparotomies
using a murine model. Am J Surg 187(2):304–308
Gynecol Surg (2012) 9:237–245 243
41. Ustun C, Kocak I, Akpolat I (2000) Effects of Seprafilm
(sodium hyaluranate-based bioresorbable), Sepracoat (0.4 %
hyaluronic acid), and Ringer’s lactate on the prevention of
postsurgical adhesion formation in rat models. J Obstet Gynaecol
20(1):78–80
42. Eroglu A, Demirci S, Kurtman C, Akbay A, Eroglu N (2001)
Prevention of intra-abdominal adhesions by using Seprafilm in
rats undergoing bowel resection and radiation therapy. Colorectal
Dis 3(1):33–37
43. Ghellai AM, Stucchi AF, Lynch DJ, Skinner KC, Colt MJ, Becker
JM (2000) Role of a hyaluronate-based membrane in the preven-
tion of peritonitis-induced adhesions. J Gastrointest Surg 4
(3):310–315
44. Adanali G, Verdi M, Tuncel A, Erdogan B, Kargi E (2003) Effects
of hyaluronic acid–carboxymethylcellulose membrane on extra-
neural adhesion formation and peripheral nerve regeneration. J
Reconstr Microsurg 19(1):29–36
45. Sasaki T, Shimura H, Tanaka T, Nakashima K, Matsuo K, Ikeda S
(2004) Protection of trocar sites from gallbladder cancer implanta-
tion by sodium hyaluronate carboxymethylcellulose-based biore-
sorbable membrane (Seprafilm) in a murine model [corrected].
Surg Endosc 18(2):246–251
46. Hubbard SC, Burns JW (2002) Effects of a hyaluronan-based
membrane (Seprafilm) on intraperitoneally disseminated human
colon cancer cell growth in a nude mouse model. Dis Colon
Rectum 45(3):334–341, discussion 341-334
47. Underwood RA, Wu JS, Wright MP et al (1999) Sodium
hyaluronate carboxymethylcellulose-based bioresorbable membrane
(Seprafilm)—does it affect tumor implantation at abdominal
wound sites? Dis Colon Rectum 42(5):614–618, discussion
618-619
48. Pucciarelli S, Codello L, Rosato A, Del Bianco P, Vecchiato G,
Lise M (2003) Effect of antiadhesive agents on peritoneal
carcinomatosis in an experimental model. Br J Surg 90(1):66–71
49. Mitchell JD, Lee R, Neya K, Vlahakes GJ (1994) Reduction in
experimental pericardial adhesions using a hyaluronic acid
bioabsorbable membrane. Eur J Cardiothorac Surg 8(3):149–
152
50. Mueller XM, Tevaearai HT, Augstburger M, Burki M, von
Segesser LK (1999) Prevention of pericardial adhesions with a
bioresorbable membrane. Swiss Surg 5(1):23–26
51. Ballore L, Orru F, Nicolini F, Contini SA, Galletti G, Gherli T
(2000) Experimental results of the use of hyaluronic acid based
materials (CV Seprafilm and CV Sepracoat) in postoperative peri-
cardial adhesions. Acta Biomed Ateneo Parmense 71(5):159–166
52. Karakurum G, Buyukbebeci O, Kalender M, Gulec A (2003)
Seprafilm interposition for preventing adhesion formation after
tenolysis. An experimental study on the chicken flexor tendons. J
Surg Res 113(2):195–200
53. Garlick D, Diters R, Magee T, Joyce J, O'Callaghan M, Skrabut E
(1999) Safety Evaluation of Seprafilm(R) bioresorbable membrane
in synovial joints of New Zealand White rabbits. Toxicol Pathol 27
(6):700
54. Kasimcan MO, Bakar B, Aktas S, Alhan A, Yilmaz M (2011)
Effectiveness of the biophysical barriers on the peridural fibrosis
of a postlaminectomy rat model: an experimental research. Injury
42(8):778–781
55. Topsakal C, Akpolat N, Erol FS et al (2004) Seprafilm superior to
Gore-Tex in the prevention of peridural fibrosis. J Neurosurg 101
(2):295–302
56. Dogan S, Taskapilioglu O, Sahin S, Korfali E (2009) The
effects of Seprafilm and Interceed TC7 on epidural fibrosis in
a rat hemilaminectomy model. Neurosurg Q 19(3):190–195
57. Ozkan SB, Kir E, Culhaci N, Dayanir V (2004) The effect of
Seprafilm on adhesions in strabismus surgery—an experimental
study. J Aapos 8(1):46–49
58. Konakci E, Koyuncu M, Unal R, Tekat A, Uyar M (2004) Repair
of subtotal tympanic membrane perforations with Seprafilm. J
Laryngol Otol 118(11):862–865
59. Gago LA, Saed GM, Wang RX, Kruger M, Diamond MP (2003)
Effects of oxidized regenerated cellulose on the expression of
extracellular matrix and transforming growth factor-beta1 in
human peritoneal fibroblasts and mesothelial cells. Am J Obstet
Gynecol 189(6):1620–1625, discussion 1625-1626
60. Reijnen MM, Meis JF, Postma VA, van Goor H (1999) Prevention
of intra-abdominal abscesses and adhesions using a hyaluronic
acid solution in a rat peritonitis model. Arch Surg 134(9):997–
1001
61. Uchida K, Urata H, Mohri Y, Inoue M, Miki C, Kusunoki M
(2005) Seprafilm does not aggravate intraperitoneal septic condi-
tions or evoke systemic inflammatory response. Surg Today 35
(12):1054–1059
62. Otake K, Uchida K, Yoshiyama S et al (2008) Effects of a
hyaluronate-carboxymethylcellulose membrane (Seprafilm) on
human polymorphonuclear neutrophil functions. J Surg Res
149(2):243–249
63. Naito Y, Shin'oka T, Hibino N, Matsumura G, Kurosawa H (2008)
A novel method to reduce pericardial adhesion: a combination
technique with hyaluronic acid biocompatible membrane. J Thorac
Cardiovasc Surg 135(4):850–856
64. Bel A, Kachatryan L, Bruneval P et al (2009) A new absorbable
collagen membrane to reduce adhesions in cardiac surgery. Interact
Cardiovasc Thorac Surg 10(2):213–216
65. Galena D, Grunenwald D, Validire P, Borenstein N. Effectiveness
of a new bioabsorbable barrier in preventing pleural adhesions: a
prospective, randomized, experimental study. Paper presented at:
The 83rd Annual Meeting of the American Association for Tho-
racic Surgery, 2003; Boston, MA
66. Yilmaz O, Genc A, Taneli F, Demireli P, Deliaga H, Taneli C
(2007) Assessment of the efficacy of absorbable adhesion barriers
on dissection in esophagus operations. Int J Pediatr Otorhinolar-
yngol 71(3):409–414
67. Bahcivan M, Yucel S, Kefeli M, Gol MK, Can B, Keceligil HT
(2008) Inhibition of vein graft intimal hyperplasia by periadventitial
application of hyaluronic acid–carboxymethyl cellulose: an experi-
mental study. Scand Cardiovasc J 42(2):161–165
68. Yilmaz E, Avci M, Bulut M, Kelestimur H, Karakurt L, Ozercan I
(2010) The effect of Seprafilm on adhesion formation and
tendon healing after flexor tendon repair in chicken. Orthopedics
164–170
69. Liu Y, Skardal A, Shu XZ, Prestwich GD (2008) Prevention of
peritendinous adhesions using a hyaluronan-derived hydrogel film
following partial-thickness flexor tendon injury. J Orthop Res 26
(4):562–569
70. Magill CK, Tuffaha SH, Yee A et al (2009) The short- and
long-term effects of Seprafilm on peripheral nerves: a histological
and functional study. J Reconstr Microsurg 25(6):345–354
71. Takeuchi K, Nakazawa M, Yamazaki H et al (2009) Solid
hyaluronic acid film and the prevention of postoperative fibrous
scar formation in experimental animal eyes. Arch Ophthalmol 127
(4):460–464
72. Tsurumaru N, Arai M, Teruya K, Sueda J, Yamakawa R (2009)
Seprafilm as a new antifibrotic agent following trabeculectomy in
rabbit eyes. Jpn J Ophthalmol 53(2):164–170
73. Teruya K, Sueda J, Arai M et al (2009) Patching retinal breaks with
Seprafilm in experimental rhegmatogenous retinal detachment of
rabbit eyes. Eye 23(12):2256–2259
74. Jang CH, Park H, Cho YB, Choi CH (2008) The effect of anti-
adhesive packing agents in the middle ear of guinea pig. Int J
Pediatr Otorhinolaryngol 72(11):1603–1608
75. Tsapanos VS, Stathopoulou LP, PapathanassopoulouVS, Tzingounis
VA (2002) The role of Seprafilm bioresorbable membrane in
244 Gynecol Surg (2012) 9:237–245
the prevention and therapy of endometrial synechiae. J Biomed
Mater Res 63(1):10–14
76. van der Linden J, Duvernoy O, Hadjinikolaou L, Bengtsson L
(2001) Does hyaluronate prevent postoperative retro-sternal
adhesions in coronary surgery?—preliminary results. Eur J
Cardiothorac Surg 19(6):949–950
77. Sanders RJ, Hammond SL, Rao NM (2007) Observations on the
use of Seprafilm on the brachial plexus in 249 operations for
neurogenic thoracic outlet syndrome. Hand (N Y) 2(4):179–
183
78. Koyuncu M, Atmaca S, Ceyhan M, Erol Y (2009) Internal jugular
vein performance after functional neck dissection and the role
of Seprafilm. Trakya Universitesi Tip Fakultesi Dergisi 26
(4):322–325
79. Filler AG, Haynes J, Jordan SE et al (2005) Sciatica of nondisc
origin and piriformis syndrome: diagnosis by magnetic resonance
neurography and interventional magnetic resonance imaging with
outcome study of resulting treatment. J Neurosurg Spine 2(2):99–
115
80. Assaf A (1999) Seprafilm in repeated strabismus surgery to
reduce surgical scarring. In: Lennerstrand G (ed) Advances in
Strabismology. Aeolus, Buren, pp 377–380
81. Taban M, Nakra T, Mancini R, Douglas RS, Goldberg RA (2009)
Orbital wall fracture repair using Seprafilm. Ophthal Plast
Reconstr Surg 25(3):211–214
82. Shibata M, Sugiyama T, Kojima S, Nagamatsu S, Hayashida M,
Ikeda T (2010) A case of neovascular glaucoma treated by
trabeculectomy with adjunct use of Seprafilm. Jpn J Clin
Opthalmol 64(12):1891–1895
83. Caylan R, Bektas D (2007) Preservation of the mastoid aeration
and prevention of mastoid dimpling in chronic otitis media
with cholesteatoma surgery using hyaluronate-based bioresorb-
able membrane (Seprafilm). Eur Arch Otorhinolaryngol 264
(4):377–380
84. Ichinose T, Uda T, Kusakabe T, Murata K, Sakaguchi M (2007)
Effectiveness of antiadhesion barriers in preventing adhesion for
external decompression and subsequent cranioplasty. No Shinkei
Geka 35(2):151–154
Gynecol Surg (2012) 9:237–245 245
